Zymeworks Inc.
Zymeworks Inc. (NASDAQ: ZYME) is a global biotechnology company focused on developing and commercializing novel multifunctional biotherapeutics to address difficult-to-treat conditions including cancer, inflammation, and autoimmune disease. The company operates a business model centered on asset and royalty… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Zymeworks Inc. does
In the company’s own words
Zymeworks Inc. (NASDAQ: ZYME) is a global biotechnology company focused on developing and commercializing novel multifunctional biotherapeutics to address difficult-to-treat conditions including cancer, inflammation, and autoimmune disease. The company operates a business model centered on asset and royalty aggregation, combining internal innovation with strategic partnerships to optimize future milestone and royalty cash flows while maintaining capital allocation discipline.
The company's strategy encompasses several key pillars. Its proprietary technology platforms include the Azymetric multispecific antibody platform, which enables simultaneous binding to multiple targets and has been validated through FDA approval of zanidatamab for biliary tract cancer. Additional platforms include drug conjugate technologies featuring a proprietary topoisomerase 1 inhibitor payload, the EFECT antibody effector function modulation platform, and the ProTECT tumor-specific immune co-stimulation platform. These platforms support development of antibody-drug conjugates and multispecific antibody therapeutics targeting oncology, autoimmune, and inflammatory indications.
Zymeworks maintains a portfolio of partnered programs generating milestone and royalty revenues. Zanidatamab, marketed as Ziihera, represents the company's first internally developed product to achieve regulatory approval, with commercialization rights held by Jazz Pharmaceuticals and BeOne Medicines in different territories. The company also receives milestone payments and royalties from pasritamig, a bispecific T cell engager developed with Johnson & Johnson, and maintains platform collaboration agreements with multiple pharmaceutical partners including Celgene, GlaxoSmithKline, Daiichi Sankyo, and Merck.
The wholly-owned pipeline includes clinical-stage programs such as ZW191 and ZW251, antibody-drug conjugates targeting folate receptor alpha and glypican 3 respectively, as well as preclinical candidates including ZW209, a trispecific T cell engager, and ZW1528, a bispecific molecule for autoimmune and inflammatory diseases. In March 2026, the company entered into a royalty monetization arrangement with Royalty Pharma, securing $250 million in financing against future Ziihera royalties. The company maintains its website at www.zymeworks.com and operates as a smaller reporting company under SEC regulations.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MIDDLETOWN, DE
- Fiscal year end
- December
- CIK
- 1937653
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Zymeworks Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Zymeworks Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Zymeworks Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Zymeworks Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Zymeworks Inc.'s last four quarterly filings that the numbers alone won't show?”